Halozyme Therapeutics, Inc. (HALO)
62.88
-0.46
(-0.72%)
USD |
NASDAQ |
Dec 08, 16:00
62.05
-0.82
(-1.31%)
After-Hours: 17:53
Halozyme Therapeutics Research and Development Expense (TTM): 70.03M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Merck & Co., Inc. | 14.26B |
| ANI Pharmaceuticals, Inc. | 56.05M |
| Bristol Myers Squibb Co. | 9.719B |
| Twist Bioscience Corp. | 80.28M |
| Aurinia Pharmaceuticals, Inc. | 29.72M |